XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XTX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XTX-101 overview

XTX-101 is under development for the treatment of advanced solid tumors including colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, Head And Neck Cancer, renal cell cancer,  uterine cancer, merkel cell carcinoma, cervical cancer, esophageal cancer, prostate cancer, gastric cancer, fallopian tube cancer, leiomyosarcoma and metastatic melanoma. It acts by targeting cytotoxic T lymphocyte associated antigen 4. The drug candidate is developed based on Aklusion and Switchblade platform technology.

Xilio Therapeutics overview

Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.

For a complete picture of XTX-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.